Lucknow News Flash

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Amyotrophic Lateral Sclerosis pipeline constitutes 90+ key companies continuously working towards developing 100+ Amyotrophic Lateral Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Amyotrophic Lateral Sclerosis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market.

 

Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years. 
• Amyotrophic Lateral Sclerosis companies working in the treatment market are Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway & Ferrer, Helixmith, Sanofi/Denali Therapeutics, Transposon Therapeutics, Alector/GSK, NeuroSense Therapeutics, Biogen/Ionis, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics/Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment 

• Emerging Amyotrophic Lateral Sclerosis therapies in the different phases of clinical trials are- AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001/FNP122, Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.   
• In September 2022, RELYVRIO for ALS has been authorised by the US FDA. Sodium phenylbutyrate and taurursodiol, the two medications that make up RELYVRIO, slowed the rate of decline on a clinical assessment of daily functioning and were linked to a longer overall survival.
• In May 2022, The US FDA gave the oral ALS medication RADICAVA ORS (edaravone) approval.
• In July 2022, Tofersen (Biogen), an investigational medication for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), had its new drug application (NDA) approved by the FDA. The Prescription Drug User Fee Act date of January 25, 2023 has been assigned to the application, which has been awarded priority review status.
• In October 2021, Topline findings from the pivotal Phase 3 VALOUR study of the investigational antisense medication tofersen (BIIB067), which is being tested for persons with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), were released by Biogen Inc.

 

Amyotrophic Lateral Sclerosis Overview

One of the illnesses included in the category of motor neuron diseases is amyotrophic lateral sclerosis (ALS). The motor neurons in the brain and spinal cord, which promote communication between the nervous system and the body’s voluntary muscles, gradually degenerate and eventually die in this condition.

 

Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight

 

Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include:

• AS-202: Acurastem
• HK001: Everfront Biotech Co., Ltd
• Tegoprubart: Eledon Pharmaceuticals
• AP-101: AL-S Pharma
• BLZ945: Novartis
• ANX005: Annexon Biosceinces
• MN-166: MediciNova
• TW001/FNP122: Treeway & Ferrer
• Engensis (VM202): Helixmith
• SAR443820/DNL788: Sanofi/Denali Therapeutics
• TPN-101: Transposon Therapeutics
• Latozinemab (AL001/GSK4527223): Alector/GSK
• PrimeC: NeuroSense Therapeutics
• Tofersen (BIIB067): Biogen/Ionis
• ION363: Ionis Pharmaceuticals
• NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
• Reldesemtiv: Cytokinetics/Astellas Pharma
• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
• Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences

 

Amyotrophic Lateral Sclerosis Route of Administration

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

Amyotrophic Lateral Sclerosis Molecule Type

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule 

 

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

• Amyotrophic Lateral Sclerosis Assessment by Product Type
• Amyotrophic Lateral Sclerosis By Stage and Product Type
• Amyotrophic Lateral Sclerosis Assessment by Route of Administration
• Amyotrophic Lateral Sclerosis By Stage and Route of Administration
• Amyotrophic Lateral Sclerosis Assessment by Molecule Type
• Amyotrophic Lateral Sclerosis by Stage and Molecule Type

 

DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies

 

Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics Market include:

Key companies developing therapies for Amyotrophic Lateral Sclerosis are – Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.

 

Amyotrophic Lateral Sclerosis Pipeline Analysis:

The Amyotrophic Lateral Sclerosis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
• Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies

 

Amyotrophic Lateral Sclerosis Pipeline Market Drivers

• Rising incidence of Amyotrophic Lateral Sclerosis, increasing geriatric population, improving Healthcare Infrastructure, demand for New and Effective Drugs are some of the important factors that are fueling the Amyotrophic Lateral Sclerosis Market.

 

Amyotrophic Lateral Sclerosis Pipeline Market Barriers

• However, aggressive nature of disease and the complexity of targeting the CNS, the current standard of care for patients with newly-diagnosed Amyotrophic Lateral Sclerosis has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Amyotrophic Lateral Sclerosis Market growth.

 

Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight    

• Coverage: Global
• Key Amyotrophic Lateral Sclerosis Companies: Acurastem, Everfront Biotech Co., Ltd, Eledon Pharmaceuticals, AL-S Pharma, Novartis, Annexon Biosceinces, MediciNova, Treeway & Ferrer, Helixmith, Sanofi/Denali Therapeutics, Transposon Therapeutics, Alector/GSK, NeuroSense Therapeutics, Biogen/Ionis, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics/Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, and others
• Key Amyotrophic Lateral Sclerosis Therapies: AS-202, HK001, Tegoprubart, AP-101, BLZ945, ANX005, MN-166, TW001/FNP122, Engensis (VM202), SAR443820/DNL788, TPN-101, Latozinemab (AL001/GSK4527223), PrimeC, Tofersen (BIIB067), ION363, NurOwn (MSC-NTF cells), Reldesemtiv, Pegcetacoplan (APL-2), Gold Nanocrystals/CNM-Au8, and others
• Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
• Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers 

 

Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials

 

Table of Contents

1. Amyotrophic Lateral Sclerosis Report Introduction

2. Amyotrophic Lateral Sclerosis Executive Summary

3. Amyotrophic Lateral Sclerosis Overview

4. Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics

6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)

7. Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)

8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)

9. Amyotrophic Lateral Sclerosis Preclinical Stage Products

10. Amyotrophic Lateral Sclerosis Therapeutics Assessment

11. Amyotrophic Lateral Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Amyotrophic Lateral Sclerosis Key Companies

14. Amyotrophic Lateral Sclerosis Key Products

15. Amyotrophic Lateral Sclerosis Unmet Needs

16 . Amyotrophic Lateral Sclerosis Market Drivers and Barriers

17. Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion

18. Amyotrophic Lateral Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services